Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)
This study has been completed.
Study NCT01431521   Information provided by Merck

First Received on September 7, 2011.   Last Updated on October 16, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Non-alcoholic Fatty Liver Disease
Additional conditions recognized in this trial
Fatty Liver
Liver Diseases
More general conditions related to this trial
Digestive System Diseases
Interventions listed in this trial
MK-4074 200 mg
Placebo for MK-4074 100 mg
Pioglitazone hydrochloride 30 mg
Additional drug interventions recognized in this trial
Pioglitazone
More general drug interventions related to this trial
Hypoglycemic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Merck


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services